Fida Biosystems
Marion Albasini's work experience includes roles as a Business Developer at Fida Biosystems since October 2020 and as a Consultant in Business Development at Novoptim from October 2020 to October 2021. Marion also worked as a Research Associate at CHUV (Centre hospitalier universitaire vaudois) from February 2019 to December 2019 and as a Master thesis student from May 2018 to January 2019. Prior to that, they were a Pre-master thesis student at the Université de Lausanne from September 2018 to December 2018.
Marion Albasini's education history is as follows:
Marion Albasini completed their Master of Science in Medical Biology from the University of Lausanne - UNIL, from 2017 to 2019. Prior to that, in 2017, they obtained a Bachelor's degree in Human Biology from the University of Lausanne. Marion also holds a Bachelor of Science in Biology from Stockholm University, which they completed from 2016 to 2017. Before that, Marion completed their Bachelor of Science in Biology from Université de Neuchâtel, specializing in general biology from 2014 to 2016. In 2013, they began their studies in Medicine at the same university, completing the first year of the Bachelor's program. Marion Albasini's secondary education was at Lycée Collège des Creusets, where they obtained their Maturité gymnasiale degree with a focus on strong mathematics and an option in biology and chemistry.
Fida Biosystems
Fida Biosystems offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.